SME Tracker: Bulk-drug firms' prospects boosted by the focus on niche molecules
CRISIL
RESEARCH
expects the prospects of small
and medium enterprises
(SMEs)
making bulk drugs to improve in the near term, because of their sharp
focus on developing niche and complex molecules. These are difficult
to manufacture but command a higher premium.
Strong
demand for formulations and increasing health insurance penetration
would also support growth.
Developments
in China have been impacting bulk-drugs players in India.
Recently,quality issues with Chinese active pharmaceutical
ingredients in hypertension drugs had prompted a global recall.
That
prompted multinationals to look at alternative sources such as India.
Further, the recent clampdown on polluting industries in China had
led to a shutdown of several bulk-drug factories. Read
More
Comments
Post a Comment